Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 4/2013

01-04-2013 | Original Contributions

Multi-Centre European Experience with Intragastric Balloon in Overweight Populations: 13 Years of Experience

Authors: Alfredo Genco, Gontrand López-Nava, Christian Wahlen, Roberta Maselli, Massimiliano Cipriano, Maria Mara Arenas Sanchez, Chantal Jacobs, Michele Lorenzo

Published in: Obesity Surgery | Issue 4/2013

Login to get access

Abstract

Background

The request to lose weight is expanding not only in obese and morbidly obese patients but also in overweight patients affected by co-morbidities as diabetes and hypertension and who do not tolerate diet regimen or lifestyle changes. The aim of this study is a multicenter evaluation of outcomes of intragastric balloon in overweight patients.

Methods

Patients (BMI 27–30 kg/m2) treated with a BioEnterics Intragastric Balloon (BIB) between 1996 and 2010 were extracted from the database of the participating centres in Rome (Italy), Liège (Belgium) and Madrid (Spain). Primary endpoints were the efficacy and safety at 6 and 42 months from balloon positioning. Secondary endpoints included resolution of co-morbidities.

Results

A total of 261 patients were included in this study. The most common indication for balloon placement was a psychological disorder (54 %). Mean body mass index (BMI) fell from 28.6 ± 0.4 at baseline to 25.4 ± 2.6 kg/m2 at 6 months and to 27.0 ± 3.1 kg/m2 at 3 years from BIB removal. The mean %EWL was 55.6 % at 6 months and 29.1 % at 3 years. Forty-seven patients (18 %) had complications associated with placement of the intragastric balloon (leak = 28, intolerance = 14, duodenal ulcer = 2, gastritis = 1, oesophagitis = 1, duodenal polyps = 1). The rate of patients with hypertension decreased from 29 % at baseline to 16 % at 3 years. Diabetes decreased from 15 to 10 %, dyslipidaemia decreased from 20 to 18 %, hypercholesterolaemia decreased from 32 to 21 % and osteoarthropathy decreased from 25 to 13 %.

Conclusions

The intragastric balloon is safe and effective in overweight patients, helping to reduce progression to obesity and decreasing the prevalence of a number of important co-morbidities.
Literature
1.
2.
Seidell JC. The impact of obesity on health status: some implications for health care costs. Int J Obesity. 1996;19 Suppl 6:S13–6.
3.
Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006;355:763–78.PubMedCrossRef
4.
Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. N Engl J Med. 1995;333:677–85.PubMedCrossRef
5.
6.
Colditz GA, Willett WC, Rotnitsky A, et al. Weight gain as a risk factor for clinical diabetes in women. Arch Intern Med. 1995;122:481–6.
7.
Chan JM, Rimm EB, Colditz GA, et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 1994;17:961–9.PubMedCrossRef
8.
Hubert HB, Feinleib M, McNamara PM, et al. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67:968–77.PubMedCrossRef
9.
Willet WC, Manson JE, Stampfer MJ, et al. Weight, weight change, and coronary heart disease in women. JAMA. 1995;273:461–5.CrossRef
10.
NIH Conference. Gastrointestinal surgery for severe obesity. Consensus development conference panel. Ann Intern Med. 1991;115:956–61.
11.
Messina T, Genco A, Favaro R, et al. Intragastric balloon positioning and removal: sedation or general anesthesia? Surg Endosc. 2011;25:3811–4.PubMedCrossRef
12.
Sallet JA, Marchesini JB, Paiva DS, et al. Brazilian multicenter study of the intragastric balloon. Obes Surg. 2004;14:991–8.PubMedCrossRef
13.
Genco A, Bruni T, Doldi SB, et al. BioEnterics Intragastric Balloon: the Italian experience with 2,515 patients. Obes Surg. 2005;15:1161–4.PubMedCrossRef
14.
Lopez-Nava G, Rubio MA, Prados S, et al. BioEnterics® Intragastric Balloon (BIB®): single ambulatory center Spanish experience with 714 consecutive patients treated with one or two consecutive balloons. Obes Surg. 2011;21:5–9.PubMedCrossRef
15.
Angrisani L, Lorenzo M, Borrelli V, et al. Is bariatric surgery necessary after intragastric balloon treatment? Obes Surg. 2006;16:1135–7.PubMedCrossRef
16.
Genco A, Cipriano M, Bacci V, et al. BioEnterics Intragastric Balloon (BIB): a short-term, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes. 2006;30:129–33.CrossRef
17.
Genco A, Balducci S, Bacci V, et al. Intragastric balloon or diet alone? A retrospective evaluation. Obes Surg. 2008;18:989–92.PubMedCrossRef
18.
Genco A, Cipriano M, Bacci V, et al. Intragastric balloon followed by diet vs intragastric balloon followed by another balloon: a prospective study on 100 patients. Obes Surg. 2010;20:1496–500.PubMedCrossRef
19.
Wadden TA, Sternberg JA, Letizia KA, et al. Treatment of obesity by a very low calorie diet, behaviour therapy, and their combination: a five-year perspective. Int J Obes. 1989;13 Suppl 2:39–46.PubMed
20.
Patrick K, Calfas KJ, Norman GJ, et al. Outcomes of a 12-month web-based intervention for overweight and obese men. Ann Behav Med. 2011;42(3):391–401.PubMedCrossRef
21.
Loveman E, Frampton GK, Shepherd J, et al. The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: a systematic review. Health Technol Assess. 2011;15(2):1–182.
22.
Pappachan JM, Chacko EC, Arunagirinathan G, et al. Management of hypertension and diabetes in obesity: non-pharmacological measures. Int J Hypertens. 2011;3:98–105.
23.
Williamson DF, Pamuk E, Thun M, et al. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40–64 years. Am J Epidemiol. 1995;141:1128–41.PubMed
Metadata
Title
Multi-Centre European Experience with Intragastric Balloon in Overweight Populations: 13 Years of Experience
Authors
Alfredo Genco
Gontrand López-Nava
Christian Wahlen
Roberta Maselli
Massimiliano Cipriano
Maria Mara Arenas Sanchez
Chantal Jacobs
Michele Lorenzo
Publication date
01-04-2013
Publisher
Springer-Verlag
Published in
Obesity Surgery / Issue 4/2013
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-012-0829-3

Other articles of this Issue 4/2013

Obesity Surgery 4/2013 Go to the issue

Letter to the Editor

Letter to the Editor and Comments on the Article “Gastric Histopathologies in Patients Undergoing Laparoscopic Sleeve Gastrectomies” by Salam Al Sabah et al.

New Concept

ProSeal™ LMA Increases Safe Apnea Period in Morbidly Obese Patients Undergoing Surgery under General Anesthesia

Clinical Report

Preoperative Fat-Free Mass: A Predictive Factor of Weight Loss after Gastric Bypass

Letter to the Editor

Obesity-Related Female Infertility in Medieval Persian Manuscripts

Clinical Research

The Hedonic Drive to Consume Palatable Foods Appears to be Lower in Gastric Band Carriers than in Severely Obese Patients Who Have Not Undergone a Bariatric Surgery

Animal Research

Longitudinal Assessment of Food Intake, Fecal Energy Loss, and Energy Expenditure After Roux-en-Y Gastric Bypass Surgery in High-Fat-Fed Obese Rats